EZH2 as a potential target in cancer therapy

Epigenomics

Volumn 6, Issue 3, 2014, Pages 341-351

  McCabe, Michael T ^a   Creasy, Caretha L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

cancer; EZH2; histone lysine methyltransferase; PRC2; small molecule inhibitor

Indexed keywords

3-DEAZANEPLANOCIN; ADENOSINE; EZH2 PROTEIN, HUMAN; MOLECULAR LIBRARY; POLYCOMB REPRESSIVE COMPLEX 2;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CHEMISTRY; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PATHOLOGY; PHARMACOLOGY;

ADENOSINE; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 2; SMALL MOLECULE LIBRARIES;

EID: 84905826842     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.23     Document Type: Review

References (90)

1. Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298(5595), 1039-1043 (2002
2. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15(1), 57-67 (2004
3. Oguchi K, Takagi M, Tsuchida R et al. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood 101(9), 3622-3627 (2003
4. Wu CT, Jones RS, Lasko PF, Gelbart WM. Homeosis and the interaction of zeste and white in Drosophila. Mol. Gen. Genet. 218(3), 559-564 (1989
5. Lee TI, Jenner RG, Boyer LA et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125(2), 301-313 (2006
6. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100(20), 11606-11611 (2003
7. Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102(7), 1298-1305 (2011
8. Varambally S, Dhanasekaran SM, Zhou M et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624-629 (2002
9. Wagener N, Macher-Goeppinger S, Pritsch M et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10, 524 (2010
10. Bodor C, O'Riain C, Wrench D et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 25(4), 726-729 (2011
11. Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42(8), 722-726 (2010
12. McCabe MT, Graves AP, Ganji G et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109(8), 2989-2994 (2012
13. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42(2), 181-185 (2010
14. Glazer RI, Hartman KD, Knode MC et al. 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun. 135(2), 688-694 (1986
15. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007
16. Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579-1588 (2009
17. Zoabi M, Sadeh R, de BP, Marquez VE, Ciechanover A. PRAJA1 is a ubiquitin ligase for the Polycomb repressive complex 2 proteins. Biochem. Biophys. Res. Commun. 408(3), 393-398 (2011
18. Beguelin W, Popovic R, Teater M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23(5), 677-692 (2013
19. Diaz E, Machutta CA, Chen S et al. Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens. J. Biomol. Screen. 17(10), 1279-1292 (2012
20. McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427), 108-112 (2012
21. Knutson SK, Warholic NM, Wigle TJ et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110(19), 7922-7927 (2013
22. Knutson SK, Wigle TJ, Warholic NM et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8(11), 890-896 (2012
23. Qi W, Chan H, Teng L et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109(52), 21360-21365 (2012
24. Verma SK, Tian X, LaFrance LV et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3(12), 1091-1096 (2012
25. Garapaty-Rao S, Nasveschuk C, Gagnon A et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem. Biol. 20(11), 1329-1339 (2013
26. Bodor C, Grossmann V, Popov N et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122(18), 3165-3168 (2013
27. Lohr JG, Stojanov P, Lawrence MS et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109(10), 3879-3884 (2012
28. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360), 298-303 (2011
29. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 150(2), 251-263 (2012
30. Cromer MK, Starker LF, Choi M et al. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J. Clin. Endocrinol. Metab. 97(9), E1774-E1781 (2012
31. Durinck S, Ho C, Wang NJ et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 1(2), 137-143 (2011
32. Saieg MA, Geddie WR, Boerner SL,Bailey D, Crump M, da Cunha SG. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples. Cancer Cytopathol. 121(7), 377-386 (2013
33. Ryan RJ, Nitta M, Borger D et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE 6(12), e28585 (2011
34. Zhang J, Grubor V, Love CL et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110(4), 1398-1403 (2013
35. Krauthammer M, Kong Y, Ha BH et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44(9), 1006-1014 (2012
36. Majer CR, Jin L, Scott MP et al. A687V EZH2 is a gain-offunction mutation found in lymphoma patients. FEBS Lett. 586(19), 3448-3451 (2012
37. Yap DB, Chu J, Berg T et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117(8), 2451-2459 (2011
38. Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumorassociated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107(49), 20980-20985 (2010
39. Wigle TJ, Knutson SK, Jin L et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 585(19), 3011-3014 (2011
40. Barski A, Cuddapah S, Cui K et al. High-resolution profiling of histone methylations in the human genome. Cell 129(4), 823-837 (2007
41. Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Mol. Cell Biol. 28(8), 2718-2731 (2008
42. Ferrari KJ, Scelfo A, Jammula S et al. Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity. Mol. Cell 53(1), 49-62 (2014
43. Velichutina I, Shaknovich R, Geng H et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116(24), 5247-5255 (2010
44. Su IH, Basavaraj A, Krutchinsky AN et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4(2), 124-131 (2003
45. Raaphorst FM, van Kemenade FJ, Blokzijl T et al. Coexpression of BMI-1 and EZH2 Polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol. 157(3), 709-715 (2000
46. Score J, Hidalgo-Curtis C, Jones AV et al. Inactivation of Polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/ myeloproliferative neoplasms. Blood 119(5), 1208-1213 (2012
47. Ernst T, Pflug A, Rinke J et al. A somatic EZH2 mutation in childhood acute myeloid leukemia. Leukemia 26(7), 1701-1703 (2012
48. Jankowska AM, Makishima H, Tiu RV et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118(14), 3932-3941 (2011
49. Abdel-Wahab O, Pardanani A, Patel J et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25(7), 1200-1202 (2011
50. Makishima H, Jankowska AM, Tiu RV et al. Novel homo-and hemi-zygous mutations in EZH2 in myeloid malignancies. Leukemia 24(10), 1799-1804 (2010
51. Ntziachristos P, Tsirigos A, Van VP et al. Genetic inactivation of the Polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18(2), 298-301 (2012
52. Simon C, Chagraoui J, Krosl J et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26(7), 651-656 (2012
53. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24(2), 268-273 (2006
54. Weikert S, Christoph F, Kollermann J et al. Expression levels of the EZH2 Polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16(2), 349-353 (2005
55. Sudo T, Utsunomiya T, Mimori K et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br. J. Cancer 92(9), 1754-1758 (2005
56. Breuer RH, Snijders PJ, Smit EF et al. Increased expression of the EZH2 Polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6(6), 736-743 (2004
57. Alajez NM, Shi W, Hui AB et al. Enhancer of zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 1, e85 (2010
58. Smits M, Nilsson J, Mir SE et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8), 710-720 (2010
59. Smits M, Mir SE, Nilsson RJ et al. Downregulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 6(1), e16282 (2011
60. Lu J, He ML, Wang L et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 71(1), 225-233 (2011
61. Zhang B, Liu XX, He JR et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32(1), 2-9 (2011
62. Friedman JM, Liang G, Liu CC et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the Polycomb group protein EZH2. Cancer Res. 69(6), 2623-2629 (2009
63. Ciarapica R, Russo G, Verginelli F et al. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 8(1), 172-175 (2009
64. Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008
65. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for Polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45(7), 639-645 (2006
66. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22(20), 5323-5335 (2003
67. Wilson BG, Wang X, Shen X et al. Epigenetic antagonism between Polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18(4), 316-328 (2010
68. Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 12(13), 2113-2119 (2013
69. Sato T, Kaneda A, Tsuji S et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci. Rep. 3, 1911 (2013
70. Lee RS, Stewart C, Carter SL et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest. 122(8), 2983-2988 (2012
71. Gadd S, Sredni ST, Huang CC, Perlman EJ. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Lab. Invest. 90(5), 724-738 (2010
72. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl Acad. Sci. USA 97(25), 13796-13800 (2000
73. Papp G, Changchien YC, Peterfia B et al. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma. Mod. Pathol. 26(3), 393-403 (2013
74. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 8(1), e55119 (2013
75. van HG, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5), 521-523 (2009
76. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43(9), 875-878 (2011
77. Robinson G, Parker M, Kranenburg TA et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488(7409), 43-48 (2012
78. Kim W, Bird GH, Neff T et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9(10), 643-650 (2013
79. Xu K, Wu ZJ, Groner AC et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycombindependent. Science 338(6113), 1465-1469 (2012
80. Sasaki D, Imaizumi Y, Hasegawa H et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 96(5), 712-719 (2011
81. Holm K, Grabau D, Lovgren K et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol. Oncol. 6(5), 494-506 (2012
82. Yan J, Ng SB, Tay JL et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 121(22), 4512-4520 (2013
83. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414(6859), 105-111 (2001
84. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997
85. Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K. The Polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell Biol. 27(10), 3769-3779 (2007
86. Onder TT, Kara N, Cherry A et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483(7391), 598-602 (2012
87. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20(9), 1123-1136 (2006
88. Natsume A, Ito M, Katsushima K et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res. 73(14), 4559-4570 (2013
89. Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem celllike side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10(2), 325-335 (2011
90. Kim E, Kim M, Woo DH et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23(6), 839-852 (2013).